Timing note: the event date provided is Monday, July 27, 2026, which is today, not tomorrow. This preview is written ahead of BRO’s 2Q26 earnings call.
Brown & Brown enters 2Q with a substantially larger revenue base following the Accession acquisition, but its core organic-growth setup remains challenging. The debate is not whether total revenue will grow sharply year over year—it almost certainly should, given the acquisition—but whether BRO can deliver on its prior message of sequentially improving organic growth, preserve margins, and demonstrate that Accession integration is progressing without disrupting sales execution.
The quarter is particularly important because 2Q is seasonally property-heavy, and management entered the year expecting continued pressure in catastrophe-exposed property pricing. That pressure is most meaningful in Specialty Distribution, where BRO has historically had greater CAT-property exposure. The offset is contingent commissions: management argues these are structurally countercyclical to softer E&S property pricing, but investors will want to distinguish recurring underwriting-profit contingents from favorable timing and prior-period true-ups.
In 1Q26, consolidated organic revenue was flat, while organic growth including contingents was 2.2%. Management attributed the weak core metric to roughly 100 bps from the absence of prior-year flood-claims processing revenue and continued CAT-property rate pressure.
The key setup for 2Q is more difficult:
Investor focus: Specialty Distribution’s ex-contingent organic growth versus management’s “relatively flat” framing, underlying policy/submission volumes, and any updated commentary on June property renewals.
Contingent commissions were the principal positive surprise in 1Q. They rose $54 million, including approximately $30 million from stronger underwriting profitability and $22 million from Accession. However, management also identified roughly $15 million tied to prior-year accrual finalization and timing of amounts that otherwise would have been recognized in late 2025.
That makes 2Q a cleaner test of the earnings model:
Investor focus: reported contingent revenue, the portion that is recurring versus timing-related, and whether management maintains or raises its full-year outlook.
Retail produced only 1.0% organic growth excluding contingents and 1.3% including contingents in 1Q. The segment has several moving pieces:
Investor focus: Retail organic growth progression despite the pharmacy headwind, sales-production indicators, and any update on lost-business revenue and litigation.
Accession is both the largest source of reported growth and the largest execution variable. BRO recorded approximately $445 million of Accession revenue in 1Q26. Because of seasonal revenue/profit phasing and the relative mix of the legacy businesses, Accession reduced consolidated adjusted EBITDAC margin by roughly 200 bps in 1Q.
Management continues to target:
Investor focus: evidence that synergy capture is on track, Attrition/producer-retention trends, incremental integration costs, and whether margin performance improves as the revenue mix normalizes.
| Metric | 2Q25 actual | 1Q26 actual | What it means for 2Q26 |
|---|---|---|---|
| Total revenue | $1.285B | $1.901B | Year-over-year reported growth should be heavily acquisition-driven. |
| Organic revenue growth | 3.6% | 0.0% | The central operational scorecard is whether core growth begins improving sequentially. |
| Organic growth incl. contingents | Not disclosed in this format | 2.2% | Investors should assess how much of growth is contingent-driven. |
| Adjusted EBITDAC margin | 36.7% | 38.5% | Margin durability remains important amid integration, softer pricing, and elevated contingents. |
| Adjusted diluted EPS | $1.03 | $1.39 | EPS comparison is complicated by acquisition financing, higher amortization, and a higher share count. |
Headline EPS may be less informative than usual. The Accession transaction has introduced several material items:
BRO repurchased approximately $350 million of shares over the preceding six months, reducing share count by about 5 million shares. Still, the investment case needs to show that organic growth, synergies, and cash generation can more than offset the deal’s financing and dilution burden.
BRO finished 1Q with $1.0 billion of cash and cash equivalents, $1.24 billion of current debt, and $6.58 billion of long-term debt. Operating cash flow was solid at $262 million, up 23% year over year, although integration costs and above-estimate earn-out payments tempered conversion.
Management’s capital-allocation priorities remain deleveraging, tuck-in/specialty M&A, dividends, technology investment, and repurchases. For 2Q, investors should look for evidence that cash generation supports those priorities without slowing debt reduction.
BRO’s 2Q report is likely to be judged primarily on organic trajectory and earnings quality, not reported growth. The company has positioned 2Q as a period of meaningful CAT-property pressure, so merely meeting headline revenue and EPS expectations may not be enough. A constructive result would show stable Specialty Distribution performance, sustained contingent commissions, retail improvement despite known headwinds, and tangible evidence that Accession is moving from a source of complexity toward a source of earnings and diversification.
The stock closed at $67.68 on Friday, July 24, 2026, down about 15% from its December 31, 2025 close but up roughly 20% from its late-May low. That recovery suggests the market may be looking for confirmation that 1Q’s weak core organic growth represented a cyclical/property-driven trough rather than a more persistent franchise-level slowdown.